Horizon scanning: Positive data reported for bavituximab in Stage IV Pancreatic Cancer
Source: BioSpace
Area: News
According to a report in Biospace, an open-label, randomised phase II study of bavituximab in combination with gemcitabine in patients with previously untreated, advanced stage IV pancreatic cancer resulted in more that a doubling of overall response rate (ORR) and a marginal improvement in overall survival (OS) when compared with gemcitabine alone (control arm).
In the trial which enrolled 70 patients, patients treated with a combination of bavituximab and gemcitabine had a 28% tumour response rate as compared to 13% in the control arm. Median OS, the primary endpoint of the trial, was 5.6 months for the bavituximab plus gemcitabine arm and 5.2 months for the control arm (hazard ratio = 0.75).
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Pancreas | Pancreatic Cancer | PET Scan | Study